Company Filing History:
Years Active: 2024
Title: The Innovations of Inventor Aneerban Bhattacharya
Introduction: Aneerban Bhattacharya is a prominent inventor based in San Mateo, California, known for his significant contributions to the field of biotechnology. With a focus on novel therapeutic methods, he has made strides in addressing complex medical challenges through his innovative ideas and patents.
Latest Patents: Aneerban Bhattacharya holds a patent titled "Methods and compositions for targeting PD-L1." This patent emphasizes the development of small interfering RNA (siRNA) molecules directed towards mRNA transcripts of CD274. The invention aims to promote the downregulation of programmed death-ligand 1 (PD-L1) expression in humans, which is crucial for the treatment of PD-L1 related diseases, including liver diseases, cancer, hepatocellular carcinoma, viral diseases, and hepatitis B. The siRNA can be composed of either unmodified nucleotides or modified nucleotides featuring altered sugars, nucleobases, linkages, or covalently bound targeting moieties.
Career Highlights: Aneerban currently works at Aligos Therapeutics, Inc., a company dedicated to discovering and developing transformative therapies for patients with liver diseases and viral infections. His work in the company is integral to advancing medical treatments and improving patient outcomes through innovative drug designs.
Collaborations: Throughout his career, Aneerban has collaborated with notable professionals in the field, including colleagues Leonid Beigelman and Megan Elizabeth Fitzgerald. These collaborations enhance the research within the team and lead to more effective solutions in the biotechnology sector.
Conclusion: Aneerban Bhattacharya exemplifies the spirit of innovation in the biotechnology field with his groundbreaking patent and ongoing work at Aligos Therapeutics, Inc. His contributions to siRNA technology have the potential to transform treatment strategies for a range of serious health conditions, making a lasting impact on the medical community and patients alike.